PortfoliosLab logo
HELX vs. ARKG
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility

Correlation

The correlation between HELX and ARKG is 0.62, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.


-0.50.00.51.0
Correlation: 0.6

Performance

HELX vs. ARKG - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Franklin Genomic Advancements ETF (HELX) and ARK Genomic Revolution Multi-Sector ETF (ARKG). The values are adjusted to include any dividend payments, if applicable.

-40.00%-20.00%0.00%20.00%40.00%NovemberDecember2025FebruaryMarchApril
13.63%
-33.07%
HELX
ARKG

Key characteristics

Sharpe Ratio

HELX:

-0.39

ARKG:

-0.11

Sortino Ratio

HELX:

-0.41

ARKG:

0.17

Omega Ratio

HELX:

0.95

ARKG:

1.02

Calmar Ratio

HELX:

-0.15

ARKG:

-0.06

Martin Ratio

HELX:

-0.85

ARKG:

-0.37

Ulcer Index

HELX:

10.70%

ARKG:

13.24%

Daily Std Dev

HELX:

23.11%

ARKG:

45.74%

Max Drawdown

HELX:

-58.75%

ARKG:

-83.59%

Current Drawdown

HELX:

-53.30%

ARKG:

-79.91%

Returns By Period

In the year-to-date period, HELX achieves a -5.98% return, which is significantly lower than ARKG's -4.65% return.


HELX

YTD

-5.98%

1M

-4.85%

6M

-11.93%

1Y

-10.95%

5Y*

0.55%

10Y*

N/A

ARKG

YTD

-4.65%

1M

-4.43%

6M

-3.61%

1Y

-5.15%

5Y*

-10.72%

10Y*

0.42%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


HELX vs. ARKG - Expense Ratio Comparison

HELX has a 0.50% expense ratio, which is lower than ARKG's 0.75% expense ratio.


Expense ratio chart for ARKG: current value is 0.75%, compared with the broader market range of 0.00% to 2.12%.0.50%1.00%1.50%2.00%
ARKG: 0.75%
Expense ratio chart for HELX: current value is 0.50%, compared with the broader market range of 0.00% to 2.12%.0.50%1.00%1.50%2.00%
HELX: 0.50%

Risk-Adjusted Performance

HELX vs. ARKG — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

HELX
The Risk-Adjusted Performance Rank of HELX is 88
Overall Rank
The Sharpe Ratio Rank of HELX is 77
Sharpe Ratio Rank
The Sortino Ratio Rank of HELX is 77
Sortino Ratio Rank
The Omega Ratio Rank of HELX is 77
Omega Ratio Rank
The Calmar Ratio Rank of HELX is 1212
Calmar Ratio Rank
The Martin Ratio Rank of HELX is 88
Martin Ratio Rank

ARKG
The Risk-Adjusted Performance Rank of ARKG is 2020
Overall Rank
The Sharpe Ratio Rank of ARKG is 1717
Sharpe Ratio Rank
The Sortino Ratio Rank of ARKG is 2525
Sortino Ratio Rank
The Omega Ratio Rank of ARKG is 2323
Omega Ratio Rank
The Calmar Ratio Rank of ARKG is 1818
Calmar Ratio Rank
The Martin Ratio Rank of ARKG is 1515
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

HELX vs. ARKG - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Franklin Genomic Advancements ETF (HELX) and ARK Genomic Revolution Multi-Sector ETF (ARKG). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


The chart of Sharpe ratio for HELX, currently valued at -0.39, compared to the broader market-1.000.001.002.003.004.00
HELX: -0.39
ARKG: -0.11
The chart of Sortino ratio for HELX, currently valued at -0.41, compared to the broader market-2.000.002.004.006.008.00
HELX: -0.41
ARKG: 0.17
The chart of Omega ratio for HELX, currently valued at 0.95, compared to the broader market0.501.001.502.002.50
HELX: 0.95
ARKG: 1.02
The chart of Calmar ratio for HELX, currently valued at -0.15, compared to the broader market0.002.004.006.008.0010.0012.00
HELX: -0.15
ARKG: -0.06
The chart of Martin ratio for HELX, currently valued at -0.85, compared to the broader market0.0020.0040.0060.00
HELX: -0.85
ARKG: -0.37

The current HELX Sharpe Ratio is -0.39, which is lower than the ARKG Sharpe Ratio of -0.11. The chart below compares the historical Sharpe Ratios of HELX and ARKG, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-1.00-0.500.000.501.00NovemberDecember2025FebruaryMarchApril
-0.39
-0.11
HELX
ARKG

Dividends

HELX vs. ARKG - Dividend Comparison

Neither HELX nor ARKG has paid dividends to shareholders.


TTM20242023202220212020201920182017
HELX
Franklin Genomic Advancements ETF
0.00%0.00%0.00%0.00%0.24%0.12%0.00%0.00%0.00%
ARKG
ARK Genomic Revolution Multi-Sector ETF
0.00%0.00%0.00%0.00%0.62%0.85%3.14%1.94%1.34%

Drawdowns

HELX vs. ARKG - Drawdown Comparison

The maximum HELX drawdown since its inception was -58.75%, smaller than the maximum ARKG drawdown of -83.59%. Use the drawdown chart below to compare losses from any high point for HELX and ARKG. For additional features, visit the drawdowns tool.


-80.00%-70.00%-60.00%-50.00%NovemberDecember2025FebruaryMarchApril
-53.30%
-79.91%
HELX
ARKG

Volatility

HELX vs. ARKG - Volatility Comparison

The current volatility for Franklin Genomic Advancements ETF (HELX) is 14.24%, while ARK Genomic Revolution Multi-Sector ETF (ARKG) has a volatility of 20.64%. This indicates that HELX experiences smaller price fluctuations and is considered to be less risky than ARKG based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


5.00%10.00%15.00%20.00%NovemberDecember2025FebruaryMarchApril
14.24%
20.64%
HELX
ARKG